Anteris Technologies (ASX:AVR) completed its initial public offering in the US, issuing 14.8 million shares at $6 each to raise gross proceeds of $88.8 million, according to a Tuesday filing with the Australian bourse.
The company's stock started trading on the Nasdaq Global Market under the ticker "AVR" on Dec. 13, the filing said.
The company will also list its Chess Depositary Interests on the Australian stock exchange under the ticker "AVR," the filing added.
The company plans to use the proceeds from the IPO to fund the development of its DurAVR transcatheter heart valve and a global clinical study for the valve to treat aortic stenosis, with remaining funds for working capital and debt repayment.
Shares of the company fell nearly 15% in recent Tuesday trade.
Price (AUD): $9.00, Change: $-1.54, Percent Change: -14.61%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。